Genomics-Enabled Drug Repositioning and Repurposing: Insights From an IOM Roundtable Activity
- Autores: Aidan Power, Adam C. Berger, Geoffrey S. Ginsburg
- Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 311, Nº. 20, 2014, págs. 2063-2064
- Idioma: inglés
- Enlaces
-
Resumen
Drug repositioning or drug repurposing (terms often used interchangeably) is the process whereby alternative uses or indications are identified for a drug. Repurposing can encompass the pursuit of novel use of a drug during its normal development cycle or after a drug has been approved and marketed. More recently the term drug repositioning has been specifically applied to the use of compounds previously discontinued from development for novel indications. The increasing costs of drug development and reduced output in the pharmaceutical industry (fewer new molecules entering drug development and higher failure rates in phase 3 trials) have led to renewed interest in drug repurposing as a potentially viable strategy to speed the delivery of new medicines to patients with unaddressed needs.1
